增强剂量CTOP方案治疗非霍奇金淋巴瘤临床观察

目的 观察增强剂量CTOP方案治疗非霍奇金淋巴瘤(NHL)的疗效及不良反应,进而探讨提高THP(吡柔比星)在联合化疗方案中的剂量强度的安全性。方法 18例初治NHL随机分为两组,分别接受常规剂量CTOP(THP 40mg/m2)和增强剂量CTOP(THP60 mg/m2)方案化疗至少2个疗程,观察疗效及不良反应。结果 增强剂量CTOP与常规剂量CTOP方案相比完全缓解率有所提高(33.3％vs 12.5％),达到完全缓解的时间也缩短(P<0.01);提高THP剂量强度后并未增加心脏毒性、脱发及骨髓抑制等不良反应的发生,两组的不良反应发生率及严重程度相仿,差异无显著性。结论 增强剂量CTOP方案治疗NHL可提高疗效而不加重不良反应,增强剂量吡柔比星可安全使用。

Clinical trial in the treatment of non-Hodgkin' s lymphoma's with escalated CTOP regimen

Objective To evaluate the response of escalated CTOP consisting of increased dose THP (60 mg/m2 )in NHL and clarify how the side effect occured especially for the occurrence of cardiotoxicity when the total dose of THP( pirarubicin) is increased. Methods From August 2001 to March 2002,18 patients with chemon-aive NHL received either escalated CTOP( n = 9) or conventional CTOP( n = 9). All these patients received 2 cycles chemotherapy at least.The response and side effect were observed after they received chemotherapy.Result Escalated CTOP achieved better complete remission rate than conventional CTOP (33. 3% vs 12. 5%). Time to achieved complete remission also was shorten( P < 0.01) . As to the side effect the escalated CTOP is similar to conventional CTOP.There is no significant difference between this two protocol. Conclusion Increasing the dose of THP consisted in CTOP regimen can improve efficacy. On the other hand, chemotherapy-induced toxicity was not significant intensified when dose of THP increased. Escalated THP can be used safely.